Hansa Biopharma Interim report January-September 2022

107131 exitnu 20/10 2022 08:03

· Total Revenue of SEK 67m in the third quarter 2022
· Positive reimbursement decisions received in Poland and Scotland
· $70 million raised in non-dilutive financing
· Imlifidase included in ESOT guidelines published in Transplant International

https://www.hansabiopharma.com/media/press-releases/2022/hansa-biopharma-interim-report-january-september-2022/

20/10 2022 08:08 exitnu 3

107132

Upcoming milestones and news flow

2022 Anti-GBM: Initiation of phase 3 study

2022 NiceR: Completion of GLP tox studies

H2 2022 AMR Phase 2 study: First data read out

H2 2022 U.S. Kidney transplantation: Complete enrollment

H2 2022/H1 2023 GBS Phase 2 study: Complete enrollment

H1 2023 U.S. Kidney transplantation: Complete randomization

H2 2023 GBS Phase 2 study: First data read out

2023 Long-term follow-up data 5-years out in kidney transplantation

2024 Kidney transplantation US: BLA submission

20/10 2022 08:19 exitnu 3

107134

I forhold til "Consensus estimates" så er indtægterne (nettoomsætningen) absolut til den rigtig side.

Revenue: Q3 2022 SEKm 67.1 - 9M 2022 SEKm 123.8.

20/10 2022 09:05 exitnu 2

107137

Hansa Biopharma: Q3 Launch and Genetic exploratory progress

https://www.redeye.se/research/858658/hansa-biopharma-q3-launch-and-genetic-exploratory-progress

(Redeye)

Idefirix accounts a relatively solid Q3 despite holiday interruptions. This is combined with collaboration genetic progress which converts earlier cash considerations into Q3 sales support. We expect a positive reaction compared with the regional equity market but be aware of the non-recurring nature of collaboration related sales support.

20/10 2022 09:07 exitnu 2

107138

"The current valuation is attractive for investors prepared to look into 2023 and beyond. Our base case value proposition is SEK 410 (Bear SEK 175 and Bull SEK 600) is under review. Hansa's Q3 result will likely trigger a positive reaction mainly based on very modest valuations, secured access to growth capital and a promising outlook over the next 12 to 24 months."

(Redeye)

20/10 2022 10:29 Urban 3

107146

Ja, men desværre har tilliden til aktien været tæt på et nulpunkt gennem længere tid.

Investorerne venter på, at se "penge i kassen" og ikke det modsatte kvartal efter kvartal. Derfor har det været en populær aktie hos shorterne i de seneste år. Men forhåbentlig ser vi en positiv resultat-vending i løbet af 2023.

Hansa Biopharma rapporterer et driftsresultat på SEK -140 millioner (-148) for tredje kvartal af 2022. Falder p.t. ca 6%.